Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ixazomib + LenDex vs Placebo + LenDex in NDMM
NCT01850524Phase 3Completed
- Sponsor
- Millennium Pharmaceuticals
- Start
- Apr 2013
- Primary completion
- Dec 2019
- Modality
- Small Molecules
- Countries
- 7
01
Overview
Phase 3, randomised, double-blind trial in multiple myeloma (MM) comparing Placebo + LenDex with Ixazomib + LenDex (2 arms). Primary endpoint: Progression Free Survival at 79 months. Started Apr 2013; status: completed.
02
Drugs
ixazomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT01850524.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01850524.